New data with daridorexant to be presented at SLEEP 2024
Allschwil, Switzerland – June 3, 2024
Originally posted here:
New data with daridorexant to be presented at SLEEP 2024
Allschwil, Switzerland – June 3, 2024
Originally posted here:
New data with daridorexant to be presented at SLEEP 2024
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan and employee share plan
Link:
Ipsen initiates a share buy-back program to cover its free employee share-allocation plan
London (UK), June 3, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments, today announces it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) protecting a group of molecules and their ability to trigger an immune response across a wide range of cancers by detaching the Hexokinase-2 (HK2) enzyme from the mitochondrial VDAC pores. The molecules are the crucial compounds in Vidac’s two drug candidates, VDA-1102 and VDA-1275.
Nicox SA Société anonyme with a registered capital of € 502,996.94
Read the original:
Number of voting rights as of May 31, 2024
Leiden, the Netherlands, June 3, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming’s management will participate in the following investor conferences in the month of June:
Read more here:
Pharming Group to participate in June investor conferences
U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves U.S. FDA clears QIAstat-Dx Gastrointestinal Panel 2 for use in clinical settings // New panel offers fast and accurate identification of up to 16 common gastrointestinal pathogens // Generates results in about one hour based on real-time PCR technology, easy access to Ct values and amplification curves
Go here to read the rest:
QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improve gastrointestinal care
ORION CORPORATION PRESS RELEASE 03 June 2024 at 09.30 EEST
Original post:
Orion is developing the Finnish life science industry in a unique collaboration project
Tired of looking in the mirror and seeing those unwanted signs of aging around your eyes? Forget going under the knife theres a new option that harnesses the power of your own body to achieve a brighter, more youthful appearance.
Platelet-Rich Plasma (PRP) injections are a revolutionary treatment offered at Eterna MedSpa & Laser Vein Center that can tackle a multitude of under-eye concerns.
The procedure uses a clients own blood plasma to tighten the skin and reduce wrinkles. How?
During the treatment, a small amount of blood is drawn and then placed in a centrifuge where it is spun at high speeds so the plasma rises to the top. The plasma is then drawn out into a syringe and injected in the under eye area.
The plasma contains proteins which strengthen and volumize the skin. In the under-eye area, rejuvenation occurs, stimulating the natural production of collagen, elastin, and hyaluronic acid.
The benefits of Platelet-Rich Plasma extend beyond just wrinkle reduction.
PRP helps with dark circles, puffiness, and shallowness under the eyes, said Kathe Malinowski, lead esthetician and Marketing Manager for Eterna MedSpa & Laser Vein Center. It also minimizes crepey skin under the eye area.
The results of the injections can last anywhere from six months to a year, depending on your individual age and skin condition.
Wondering if Platelet-Rich Plasma therapy is the right choice for you? Eterna MedSpa offers complimentary consultations with a nurse where you can discuss your goals and get a personalized treatment plan.
Dont wait any longer to achieve the beautiful, youthful eyes you deserve explore the power of PRP at Eterna MedSpa & Laser Vein Center.
For more information, please contact:
Eterna MedSpa & Laser Vein Center : 217 Vertin Boulevard : Shorewood, IL 60404 : 815.254.8888 : https://www.eternalaser.com/
[SPONSORED] Eterna MedSpa offers products that rejuvenate Jessica Knowles of Eterna MedSpa discusses the importance of skincare products. Injectables and other procedures provided by Eterna MedSpa will only take patients so far. Regular skin care is necessary to keep your skin looking smooth and youthful.
Original post:
PRP Under Eye Treatment: What You Should Know - The Herald-News
In a groundbreaking medical achievement, a team of Chinese scientists and clinicians has reportedly cured a patient of diabetes using cell therapy for the first time.
The patient, a 59-year-old man who had endured type 2 diabetes for 25 years, faced severe complications from the disease. Despite receiving a kidney transplant in 2017, he had lost most of his pancreatic islet function, which is crucial for regulating blood glucose levels, and was dependent on multiple daily insulin injections.
I think this study represents an important advance in the field of cell therapy for diabetes, Timothy Kieffer, a professor in the Department of Cellular and Physiological Sciences at the University of British Columbia, told South China Morning Post (SCMP) on Monday.
Global researchers are investigating islet transplants as a promising alternative treatment, primarily focusing on creating islet-like cells from human stem cell cultures. After more than a decade of effort, the Chinese team has made significant progress.
In July 2021, the patient underwent the cell transplant. Just 11 weeks later, he no longer required external insulin, and within a year, his need for oral medication to control blood sugar levels was completely eliminated.
The team, led by Yin Hao, a leading researcher at Shanghai Changzheng Hospital, used and programmed the patients own peripheral blood mononuclear cells. These were transformed into seed cells and reconstituted pancreatic islet tissue in an artificial environment.
Yin emphasized that this breakthrough is another advancement in the field of regenerative medicine, which leverages the bodys own regenerative capabilities to treat illness.
A common challenge in translational research is differentiating stem cells into high-quality insulin-producing cells on a large scale for therapeutic use. In a study published in Stem Cell Research & Therapy earlier this year, a team of diabetes researchers led by Kieffer explored methods to enhance scalable manufacturing.
They identified key parameters for monitoring quality during cell therapy production. Their findings offer valuable insights into the large-scale production of human pluripotent stem cell (hPSC)-derived pancreatic cells and propose ways to standardize the manufacturing process.
While preclinical data from Kieffers team supports using stem cell-derived islets for type 2 diabetes treatment, Yins report represents the first evidence in humans, according to Kieffer.
Chinas diabetic population is disproportionately high, notes Huang Yanzhong, a senior fellow for global health at the Council on Foreign Relations. He highlighted that although China comprises 17.7% of the worlds population, its diabetic population constitutes a staggering quarter of the global total, imposing a significant health burden on the government.
China has the highest number of people with diabetes globally. According to the International Diabetes Federation, the country has 140 million people with diabetes, with around 40 million of them dependent on lifelong insulin injections.
If this cell therapy approach proves successful, Kieffer told SCMP that, it can free patients from the burden of chronic medications, improve health and quality of life, and reduce healthcare expenditures.
However, he emphasized that further studies involving more patients, based on the findings of this Chinese study, are necessary to achieve these outcomes.
NEWSLETTER
Stay up-to-date on engineering, tech, space, and science news with The Blueprint.
Srishti Gupta Srishti studied English literature at the University of Delhi and has since then realized it's not her cup of tea. She has been an editor in every space and content type imaginable, from children's books to journal articles. She enjoys popular culture, reading contemporary fiction and nonfiction, crafts, and spending time with her cats. With a keen interest in science, Srishti is particularly drawn to beats covering medicine, sustainability, gene studies, and anything biology-related.
Read the rest here:
World's first diabetes cure with cell therapy achieved in China - Interesting Engineering
image:
A safer regenerative medicine process that removes the risk of tumor formation.
Credit: Atsushi Intoh
Ikoma, Japan Pluripotent stem cells (PSCs) are a type of stem cells capable of developing into various cell types. Over the past few decades, scientists have been working towards the development of therapies using PSCs. Thanks to their unique ability to self-renew and differentiate (mature) into virtually any given type of tissue, PSCs could be used to repair organs that have been irreversibly damaged by age, trauma, or disease.
However, despite extensive efforts, regenerative therapies involving PSCs still have many hurdles to overcome. One being the formation of tumors (via the process of tumorigenesis) after the transplantation of PSCs. Once the PSCs differentiate into a specific type for stem cell therapy, there is a high probability of tumor formation after differentiated stem cells are introduced to the target organ. For the success of PSC-based therapies, the need of the hour is to minimize the risk of tumorigenesis by identifying potentially problematic cells in cultures, prior to transplantation.
Against this backdrop, a research team led by Atsushi Intoh and Akira Kurisaki from Nara Institute of Science and Technology, Japan, has recently achieved a breakthrough discovery regarding stem cell therapy and tumorigenesis. Our findings present advancements that could bridge the gap between stem cell research and clinical application, says Intoh, talking about the potential of their findings. Their study was published in Stem Cells Translational Medicine and focuses on a membrane protein called EPHA2, which was previously found to be elevated in PSCs prior to differentiation by the team.
Through several experiments involving both mouse and human stem cell cultures, the researchers gained insights into the role of EPHA2 in preserving the potency of PSCs to develop into several cell types. They found that EPHA2 in stem cells is co-expressed with OCT4a transcription factor protein which controls the expression of genes which are critically involved in the differentiation of embryonic stem cells. Interestingly, when the EPHA2 gene was knocked down from the cells, cultured stem cells spontaneously differentiated. These results suggest that EPHA2 plays a central role in keeping stem cells in an undifferentiated state.
The researchers thus theorized that EPHA2-expressing stem cells, which would fail to differentiate, might be responsible for tumorigenesis upon transplantation into the target organ.
To test this hypothesis, the researchers prepared PSC cultures and artificially induced their differentiation into liver cells. Using a magnetic antibody targeting EPHA2, they extracted EPHA2-positive cells from a group of cultures prior to transplantation into mice. Interestingly, the formation of tumors in mice receiving transplants from cultures from which EPHA2 had been removed was vastly suppressed.
Taken together, these results point to the importance of EPHA2 in emerging stem cell-based therapies. EPHA2 conclusively emerges as a potential marker for selecting undifferentiated stem cells, providing a valuable method to decrease tumorigenesis risks after stem cell transplantation in regenerative treatments, remarks Kurisaki.
Further in-depth studies on this protein may lead to the development of protocols that make PSCs safer to use. Luckily, however, these findings pave the way towards a future where we will be able to finally restore damaged organs and even overcome degenerative conditions.
###
Resource
Title: EPHA2 is a novel cell surface marker of OCT4-positive undifferentiated cells during the differentiation of mouse and human pluripotent stem cells.
Authors: Atsushi Intoh, Kanako Watanabe-Susaki, Taku Kato, Hibiki Kiritani, Akira Kurisaki
Journal: Stem Cells Translational Medicine
DOI: 10.1093/stcltm/szae036
Information about Laboratory for Stem Cell Technologies can be found at the following website: https://bsw3.naist.jp/eng/courses/courses215.html
About Nara Institute of Science and Technology (NAIST)
Established in 1991, Nara Institute of Science and Technology (NAIST) is a national university located in Kansai Science City, Japan. In 2018, NAIST underwent an organizational transformation to promote and continue interdisciplinary research in the fields of biological sciences, materials science, and information science. Known as one of the most prestigious research institutions in Japan, NAIST lays a strong emphasis on integrated research and collaborative co-creation with diverse stakeholders. NAIST envisions conducting cutting-edge research in frontier areas and training students to become tomorrow's leaders in science and technology.
Stem Cells Translational Medicine
Experimental study
Animals
EPHA2 is a novel cell surface marker of OCT4-positive undifferentiated cells during the differentiation of mouse and human pluripotent stem cells.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
See the rest here:
Tackling the hurdle of tumor formation in stem cell therapies - EurekAlert